Ron S. Gejman

1.7k total citations
11 papers, 403 citations indexed

About

Ron S. Gejman is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ron S. Gejman has authored 11 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 8 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ron S. Gejman's work include CAR-T cell therapy research (7 papers), Immunotherapy and Immune Responses (6 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Ron S. Gejman is often cited by papers focused on CAR-T cell therapy research (7 papers), Immunotherapy and Immune Responses (6 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Ron S. Gejman collaborates with scholars based in United States, Russia and Canada. Ron S. Gejman's co-authors include David A. Scheinberg, Aaron Y. Chang, Claire Y. Oh, Tao Dao, Elliott J. Brea, Casey A. Jarvis, Andrea Schietinger, A. Ari Hakimi, Melissa Mathias and Dmitry Pankov and has published in prestigious journals such as Cell, Journal of Clinical Investigation and Blood.

In The Last Decade

Ron S. Gejman

11 papers receiving 394 citations

Peers

Countries citing papers authored by Ron S. Gejman

Since Specialization

Citations

This map shows the geographic impact of Ron S. Gejman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron S. Gejman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron S. Gejman more than expected).

Fields of papers citing papers by Ron S. Gejman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron S. Gejman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron S. Gejman. The network helps show where Ron S. Gejman may publish in the future.

Co-authorship network of co-authors of Ron S. Gejman

This figure shows the co-authorship network connecting the top 25 collaborators of Ron S. Gejman. A scholar is included among the top collaborators of Ron S. Gejman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron S. Gejman. Ron S. Gejman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Scalable generation and functional classification of genetic variants in inborn errors of immunity to accelerate clinical diagnosis and treatment 2025 ·Cell ·(unknown), Chris J. Frangieh, Neeharika Kothapalli, Jay A. Levy, (unknown), Johannes C. Melms, Ron S. Gejman, Parin Shah, (unknown), (unknown), (unknown), Lei Huang, (unknown), Dusan Bogunovic, Joshua D. Milner, Benjamin Izar	1
2	Cytokine response over the course of COVID-19 infection in pregnant women 2022 ·Cytokine ·(unknown), Elisabeth A. Murphy, Ron S. Gejman, Allyson Capili, (unknown), Sophie Rand, Kristen Cagino, Shannon Glynn, (unknown), (unknown), Jim Yee, Malavika Prabhu, Laura E. Riley, Yawei J. Yang	10
3	Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment 2022 ·Blood Advances ·Christopher M. Bourne, (unknown), Tao Dao, (unknown), (unknown), Ron S. Gejman, Andrew W. Daman, Katsuyoshi Takata, Christian Steidl, Martin G. Klatt, David A. Scheinberg	6
4	Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform 2020 ·Cancer Immunology Research ·Ron S. Gejman, (unknown), Martin G. Klatt, Aaron Y. Chang, Claire Y. Oh, Smita S. Chandran, (unknown), (unknown), Tao Dao, Christopher A. Klebanoff, David A. Scheinberg	26
5	An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments 2020 ·Journal of Proteomics ·Martin G. Klatt, (unknown), Michael Curcio, Ron S. Gejman, (unknown), David A. Scheinberg	2
6	Rejection of immunogenic tumor clones is limited by clonal fraction 2018 ·eLife ·Ron S. Gejman, Aaron Y. Chang, (unknown), (unknown), A. Ari Hakimi, Andrea Schietinger, David A. Scheinberg	79
7	Identification of Cross-Reactive Targets of TCR-Based Therapeutic Agents within the Human Proteome 2017 ·Blood ·Ron S. Gejman, Tao Dao, David A. Scheinberg	1
8	A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens 2017 ·Journal of Clinical Investigation ·Aaron Y. Chang, Tao Dao, Ron S. Gejman, Casey A. Jarvis, Andrew Scott, Leonid Dubrovsky, Melissa Mathias, Tatyana Korontsvit, Victoriya Zakhaleva, Michael Curcio, Ronald C. Hendrickson, Liu C, David A. Scheinberg	68
9	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells 2016 ·Cancer Immunology Research ·Elliott J. Brea, Claire Y. Oh, Eusebio Manchado, Sadna Budhu, Ron S. Gejman, George Mo, Patrizia Mondello, James E. Han, Casey A. Jarvis, David Ulmert, Qing Xiang, Aaron Y. Chang, Ralph Garippa, Taha Merghoub, Jedd D. Wolchok, Neal Rosen, Scott W. Lowe, David A. Scheinberg	128
10	Opportunities and challenges for TCR mimic antibodies in cancer therapy 2016 ·Expert Opinion on Biological Therapy ·Aaron Y. Chang, Ron S. Gejman, Elliott J. Brea, Claire Y. Oh, Melissa Mathias, Dmitry Pankov, Emily Casey, Tao Dao, David A. Scheinberg	46
11	T cell receptor mimic antibodies for cancer therapy 2015 ·OncoImmunology ·Leonid Dubrovsky, Tao Dao, Ron S. Gejman, Elliott J. Brea, Aaron Y. Chang, Claire Y. Oh, Emily Casey, Dmitry Pankov, David A. Scheinberg	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact